uniQure (QURE) Q4 2025 earnings review
FDA Shutters Accelerated Approval Hopes; Pipeline Execution Stalls
uniQure's investment thesis took a severe blow this quarter. The FDA officially rejected the company's Phase I/II data and external control arm as sufficient evidence for AMT-130's marketing application in Huntington's disease, instead demanding a randomized, sham-controlled Phase III trial. This permanently reverses management's prior confident guidance for an imminent BLA submission. Compounding the regulatory disaster, clinical execution is faltering: dosing in the mid/high cohorts of the AMT-191 (Fabry) program was paused due to dose-limiting toxicities (DLTs), while the AMT-162 (ALS) trial remains on voluntary pause for similar reasons. The sole saving grace is the company's massive cash balance of $622.5 million, which secures their runway through 2029 and protects against near-term dilution while they go back to the drawing board.
🐂 Bull Case
A massive $404.2 million capital raise in 2025 fortified the balance sheet, providing $622.5 million in total cash. This guarantees runway into the second half of 2029, allowing the company to absorb trial delays without facing immediate insolvency or punishing dilution.
Despite the FDA's rejection of the external control methodology, the 36-month Phase I/II data is objectively strong: a 75% slowing in disease progression (cUHDRS) and an 8.2% mean reduction in NfL vs baseline at 36 months, proving the drug has measurable therapeutic impact.
🐻 Bear Case
The FDA's mandate for a prospective, randomized, double-blind, sham surgery-controlled study adds years of delay and hundreds of millions of dollars in unexpected costs, entirely destroying the 2026 BLA submission and launch thesis.
The AMT-191 (Fabry) program has been paused at higher doses due to Grade 3 liver enzyme elevations, joining the AMT-162 (ALS) program which is already paused due to a serious adverse event. A broader pattern of vector/dose toxicity appears to be emerging.
⚖️ Verdict: 🔴🔴
Highly Bearish. The near-term commercial thesis for uniQure is dead. While the cash runway provides survival, the simultaneous collapse of the AMT-130 accelerated regulatory path and the toxicity pauses in two other key clinical assets leaves investors with no clear catalysts and a multi-year wait for a Phase III trial readout.
Key Themes
FDA Demands Phase III Trial for AMT-130
Reversing previous optimism, the FDA formally concluded that data from the Phase I/II studies compared to an external control (Enroll-HD) is insufficient to support a marketing application. The FDA strongly recommended a prospective, randomized, double-blind, sham-controlled study. Management will request a Type B meeting in Q2 2026 to discuss Phase III study design. This wipes out the commercial launch plan and necessitates a massive, complex, multi-year surgical trial.
Dose-Limiting Toxicities Plague Broader Pipeline
Decelerating clinical momentum is evident as uniQure paused additional dosing in the mid- and high-dose cohorts of its AMT-191 (Fabry disease) trial. This pause was triggered per protocol due to asymptomatic Grade 3 liver enzyme elevations in two patients, confirmed as dose-limiting toxicities (DLTs). Meanwhile, the AMT-162 (ALS) trial remains on voluntary pause following an independent monitoring committee recommendation related to a previously reported severe adverse event. These back-to-back safety signals raise critical questions about therapeutic windows across the platform.
Strong 36-Month AMT-130 Efficacy Data
Lost in the regulatory disaster is the fact that AMT-130 demonstrated highly compelling long-term data. Topline 36-month efficacy results for 12 high-dose patients showed a statistically significant 75% slowing in disease progression measured by cUHDRS compared to the propensity score-matched external control (p=0.003). Crucially, a mean reduction in the neurodegeneration biomarker NfL of -8.2% from baseline was observed at 36 months, pointing to true disease modification. The drug works; the regulatory pathway failed.
Epilepsy Asset (AMT-260) Offers Only Near-Term Clinical Catalyst
With the lead asset delayed and other programs paused, the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy (MTLE) takes on outsized importance. Management successfully completed enrollment of the first cohort (six patients) and initiated a second dose cohort. An initial read of the first patient showed a 92% reduction in seizure frequency over five months. Additional data is slated for the first half of 2026.
Other KPIs
Accelerating. Up $12.8 million YoY, driven largely by $9.4 million in professional fees, which notably included $6.5 million in costs entirely dedicated to preparing for the planned US commercialization of AMT-130. Given the FDA's requirement for a Phase III trial, these commercial preparation expenses were ultimately premature and represent dead capital.
Stable compared to $143.8 million in FY24. The relatively flat YoY profile masks an underlying mix shift: a $25.0 million decrease in personnel and facility costs due to the 2024 divestment of the Lexington facility offset a $19.4 million surge in direct R&D costs dedicated to preparing the now-defunct Biologics License Application (BLA) submission for AMT-130.
Decelerating significantly from $27.1 million in 2024. The $11.0 million drop was driven by a $10.7 million decrease in collaboration revenue and a $6.1 million reduction in contract manufacturing (following the Lexington facility sale), partially offset by a $5.8 million bump in license revenues.
Guidance
Stable. Boosted by over $404 million in net proceeds from a highly timed public offering in 2025, the company's total liquidity sits at $622.5 million. This affords management extensive flexibility to endure the multi-year delay now required for the AMT-130 Phase III trial without returning to capital markets.
Reversing. In previous quarters, guidance centered around finalizing BLA submissions. Now, guidance has retreated to the clinical development phase, aiming to meet with the FDA to discuss 'potential study design approaches' for the newly mandated Phase III sham-controlled trial.
Stable. The company expects to present updated clinical safety and exploratory efficacy data from its Phase I/IIa study in refractory mesial temporal lobe epilepsy (MTLE).
Key Questions
Phase III Trial Economics and Timeline
Given the FDA's mandate for a sham surgery-controlled trial, what are your initial estimates for the cost, enrollment timeline, and eventual data readout for a full AMT-130 Phase III study?
Commercial Expense Reversals
You spent $6.5 million in FY25 explicitly on AMT-130 commercialization prep and hired heavily into commercial/medical affairs. Do you plan to immediately wind down these divisions to preserve capital now that approval is years away?
Systemic Vector Toxicity
With dose-limiting toxicities halting progression in the AMT-191 program and causing a continued pause in the AMT-162 program, are you identifying any systemic safety issues with your specific vectors at higher doses?